A Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer Harboring KRAS G12R Mutations
Phase of Trial: Phase II
Latest Information Update: 13 Apr 2018
At a glance
- Drugs Selumetinib (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 10 Apr 2018 Status changed from active, no longer recruiting to suspended.
- 29 Mar 2018 Status changed from recruiting to active, no longer recruiting.